Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Well, the whole market is around $3B, comprised of the original (Neulasta) plus several biosimilars. In the 2nd Quarter, one of the biosimilars, Udenyca made by Coherus, had Net Sales of $135.7M (that's the only drug they sell currently). Coherus' market cap is 1.356B and Spectrum's MC is about 43% of that. It stands to reason that Spectrum can double its MC if Rolontis sales are comparable. When you listen to Spectrum's CCs, management talks confidently about selling Rolontis. I didn't have much conviction that they would be able to do so except for the fact Coherus is getting some decent sales. Recently, I've gone to believing Rolontis sales will be more significant than that but I still need to do a little more research in confirming that belief and will comment on this sometime before the PDUFA date. But if you want to do your research check out the competition in the Medicare Part D space. I believe Rolontis will be at a strong advantage against the biosimilars and will be competing mano a mano against Neulasta.

PS Don't forget the possibility of news for poziotibib filing a NDA for NSCLC exon 20 Her 2 around the end of the year if their pre-NDA meeting w the FDA, tentatively scheduled in the next month or so, is positive.